No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NKGN NKGEN BIOTECH
- 1.200
- +0.010+0.84%
Close Jun 20 16:00 ET
- 1.210
- +0.010+0.83%
Post 18:33 ET
29.87MMarket Cap-316P/E (TTM)
1.250High1.200Low70.95KVolume1.210Open1.190Pre Close86.71KTurnover0.61%Turnover RatioLossP/E (Static)24.89MShares12.88052wk High-0.54P/B14.07MFloat Cap0.78052wk Low--Dividend TTM11.72MShs Float12.880Historical High--Div YieldTTM4.20%Amplitude0.780Historical Low1.222Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | NKGen Biotech Presents Novel Manufacturing And Cryopreservation Process For Allogeneic NK Cell Therapy SNK02; CEO Dr. Paul Y. Song Updates On Initial Phase 1 Results For Treating Advanced Refractory Solid Tumors
Express News | NKGen Biotech - Snk02 Was Safe and Treatment Appeared to Stop Progression of Several Heavily Pretreated Solid Tumors as a Monotherapy
Express News | NKGen Biotech - Snk02 Appears to Have Some Clinical Activity Against Pretreated Solid Tumors Despite Lack of Lymphodepletion
Express News | NKGen Biotech Inc - Snk02 Was Found to Be Well Tolerated as a Monotherapy
Express News | NKGen Biotech To Present Updated Phase 1 Data Of SNK02 Allogeneic NK Cell Therapy In Solid Tumors At 6th Annual Allogeneic Cell Therapies Summit 2024
Express News | NKGen Biotech to Present Updated Phase 1 Data on Snk02 Allogeneic Nk Cell Therapy in Solid Tumors at the 6TH Annual Allogeneic Cell Therapies Summit 2024
Comments
$NKGEN BIOTECH(NKGN.US$ Ever notice that certain tickers the minute they make a move to the upside. Get shorted instantly! Hehehe. $Icecure Medical(ICCM.US$ Is another one! As soon as it gets any good news and starts up, its immediately driven down! Grrrr
2
$NKGEN BIOTECH(NKGN.US$ NKGen Biotech - Snk02 Was Safe and Treatment Appeared to Stop Progression of Several Heavily Pretreated Solid Tumors as a Monotherapy
1
$NKGEN BIOTECH(NKGN.US$
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGen Biotech (Nasdaq: NKGN) announced that CEO Paul Y. Song, MD, will present updated Phase 1 data on their SNK02 allogeneic NK cell therapy at the 6th Annual Allogeneic Cell Therapies Summit, June 10-12, 2024, in Boston, MA. The presentation, scheduled for June 12, will highlight the company's cryopreserved alloge...
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGen Biotech (Nasdaq: NKGN) announced that CEO Paul Y. Song, MD, will present updated Phase 1 data on their SNK02 allogeneic NK cell therapy at the 6th Annual Allogeneic Cell Therapies Summit, June 10-12, 2024, in Boston, MA. The presentation, scheduled for June 12, will highlight the company's cryopreserved alloge...
NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease.
NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on developing and commercializing innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapeutics, has announced a significant milestone. The company's cryopreserved autologous enhanced SN...
NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on developing and commercializing innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapeutics, has announced a significant milestone. The company's cryopreserved autologous enhanced SN...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg